Skip to main content

Table 1 Patients’ characteristics and clinicopathological features

From: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer

Age median (range), (y.o.)

50 (33–74)

Metastatic de-novo or recurrent, (n)

 Metastatic de-novo

10 (27.8%)

 Metastatic recurrent

26 (72.2%)

Subtype

 Luminal

29 (80.6%)

 Triple negative

7 (19.4%)

Number of previous chemotherapy regimens, (n)

 0

22 (61.1%)

 1

10 (27.8%)

 2

2 (5.6%)

3

2 (5.6%)

Previous endocrine therapy, (n)

26 (72.2%)

Metastatic sites, (n)

 Visceral

23 (63.9%)

 Non-visceral

13 (36.1%)